SAB BIOTHERAPEUTICS, INC.
SAB BIOTHERAPEUTICS, INC. (SABS): 16 pipeline candidates · 4 upcoming catalysts · ~22 mo cash runway · 15 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
22.0 months
D/E 0.09 · 0% dilution
Lead: Approved
16 candidates
4 upcoming, next in ~12d
N/A
A transparent, data-derived signal for SAB BIOTHERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$254.6M
Cash
$20.5M
Quarterly Burn
$14.3M
Runway
22.0 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (16 candidates)
| Drug | Phase |
|---|---|
| a2b395 | Phase 1/Phase 2 |
| a2b543 | Phase 1/Phase 2 |
| a2b694 | Phase 1/Phase 2 |
| alk202 | Phase 2 |
| ebanga | Approved |
| elamipretide | Phase 4 |
| elamipretide | Phase 4 |
| high dose sab-142 | Phase 2 |
| ivb102 | Early Phase 1 |
| low dose sab-142 | Phase 2 |
Showing 10 of 16 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
77
Total value held
$246.5M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 12,863,486 | $49.3M |
| caligan partners lp | 7,967,207 | $30.5M |
| vanguard capital management llc | 4,987,474 | $19.1M |
| commodore capital lp | 4,401,500 | $16.9M |
| ra capital management, l.p. | 4,401,500 | $16.9M |
| balyasny asset management l.p. | 3,760,439 | $14.4M |
| adage capital partners gp, l.l.c. | 3,405,553 | $13.0M |
| millennium management llc | 3,032,697 | $11.6M |
| spruce street capital lp | 2,198,502 | $8.4M |
| sessa capital im, l.p. | 2,198,457 | $8.4M |
Showing top 10 of 77 institutional holders of SAB BIOTHERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SAB BIOTHERAPEUTICS, INC.'s pipeline?
SAB BIOTHERAPEUTICS, INC. (SABS) has 16 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SAB BIOTHERAPEUTICS, INC.'s lead drug candidate?
SAB BIOTHERAPEUTICS, INC.'s most advanced tracked candidate is a2b395 (Phase 1/Phase 2) for Solid Tumor, Adult.
What is SAB BIOTHERAPEUTICS, INC.'s next catalyst?
SAB BIOTHERAPEUTICS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: An Open, Multicenter Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics " — expected June 30, 2026.
What is SAB BIOTHERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SAB BIOTHERAPEUTICS, INC. has approximately 22.0 months of cash runway.
What is SAB BIOTHERAPEUTICS, INC.'s market capitalization?
SAB BIOTHERAPEUTICS, INC.'s market capitalization is approximately $254.6M.
Get the full picture on SAB BIOTHERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.